Statement of Changes in Beneficial Ownership (4)
October 12 2021 - 7:41AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Clark Kenneth A |
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc.
[
SMMT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/7/2021 |
|
(Street)
CAMBRIDGE, MA 02142
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | $5.03 | 10/7/2021 | | A | | 200000 | | (1) | 10/7/2031 | Common Stock | 200000 | (3) | 200000 | D | |
| Stock Option (right to buy) | $5.03 | 10/7/2021 | | A | | 6250 | | (2) | 10/7/2031 | Common Stock | 6250 | (3) | 206250 | D | |
| Explanation of Responses: |
| (1) | The option was granted on October 7, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 7, 2022. |
| (2) | The option was granted on October 7, 2021 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. |
| (3) | Not applicable. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Clark Kenneth A
C/O SUMMIT THERAPEUTICS INC.
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE, MA 02142 | X |
|
|
|
Signatures
|
| /s/ Kenneth A. Clark | | 10/11/2021 |
| **Signature of Reporting Person | Date |
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024
